Print this page
-
GS-US-592-6173-A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1.
Protocol: 042204Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast -
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer.
Protocol: 052001Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Breast -
A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer.
Protocol: 042012Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
An Open-Label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Protocol: 052011Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Breast
Esophagus
Lung -
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.
Protocol: 192004Principal Investigator:
- Christian Hinrichs (Rutgers University)
Applicable Disease Sites: Any Site
Stomach
Breast
Lung
Cervix -
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast